On 23 March, Alzheimer Europe (AE) hosted an online Company Round Table meeting, attended by representatives from Biogen, Eisai, EFPIA, GE Healthcare, GSK, Hoffmann-La Roche, Lilly, Novo Nordisk and TauRx. Also in attendance, were members of the AE staff and representatives of AE member organisations. David Jefferys from EISAI and chair of the EFPIA Alzheimer’s Dementia Special Interest Group addressed delegates with a presentation on the implementation of the clinical trials regulations and highlighted the new Clinical Trials Regulation that entered into application on 31 January 2022.
Jean Georges updated sponsors and other delegates on Alzheimer Europe’s activities during the past year. It was also an opportunity to highlight Alzheimer Europe’s planned activities for 2022. Project Officer Cindy Birck gave then an overview of recent developments with regards to our Clinical Trials Watch database. Policy Officer Owen Miller shared some recent policy developments at the WHO and EU levels. Finally, Nicolas Creff from EFPIA gave an update on the Innovative Health Initiative (IHI). We would like to thank our sponsors and members for participating in this meeting and we look forward to welcoming them to the next Company Round Table meeting, on 14 June 2022.
